Search results
Results from the WOW.Com Content Network
[8] [9] MIS-C has also been monitored as a potential, rare [10] pediatric adverse event following COVID-19 vaccination. [11] Research suggests that COVID-19 vaccination lowers the risk of MIS-C, and in cases where symptoms develop after vaccine, is likely extremely rare or related to factors like recent exposure to COVID-19. [12]
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring. It should be contrasted with pre-exposure prophylaxis , which is used before the patient has been exposed to the infective agent.
For premium support please call: 800-290-4726 more ways to reach us
The American Assn. of Pediatrics reported that more than 7 million children have had COVID in the U.S. since the start of the pandemic, representing 17.2% of cases overall.
A systematic review notes that children with COVID-19 have milder effects and better prognoses than adults. [2] [3] However, children are susceptible to "multisystem inflammatory syndrome in children" (MIS-C), a rare but life-threatening systemic illness involving persistent fever and extreme inflammation following exposure to the SARS-CoV-2 ...
However, some people continue to experience a range of effects, such as fatigue, for prolonged periods after an initial COVID-19 infection. [20] This is the result of a condition called long COVID, which can be described as a range of persistent symptoms that continue for months or years. [20]
The rare simultaneous occurrence of thrombocytopenia (low blood platelets) with blood clots after vaccination raised the original concern about this condition. [citation needed] In many cases where acute thrombosis and thrombocytopenia have been found together after COVID‑19 vaccination, an antibody against platelet factor 4 has been ...